RedHill Biopharma (RDHL) Leases (2019 - 2025)

RedHill Biopharma (RDHL) has 7 years of Leases data on file, last reported at $1.1 million in Q4 2025.

• On a quarterly basis, Leases rose 250.0% year-over-year to $1.1 million in Q4 2025; TTM through Dec 2025 was $1.1 million, a 250.0% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 250.0% from the prior year.
• Leases for Q4 2025 stood at $1.1 million, up from $163000.0 in the prior quarter.
• Over the last five years, Leases for RDHL reached as high as $7.7 million in Q1 2022 and fell as low as $163000.0 in Q2 2025.
• Historically, Leases has averaged $3.7 million across 5 years, with a median of $4.2 million in 2021.
• Across the five-year window, Leases slumped 85.22% in 2023 and jumped 250.0% in 2025, its largest moves.
• Year by year, Leases stood at $3.7 million in 2021, then soared by 83.29% to $6.7 million in 2022, then slumped by 85.22% to $989000.0 in 2023, then slumped by 69.46% to $302000.0 in 2024, then soared by 250.0% to $1.1 million in 2025.
• Per Business Quant data, the three most recent Leases figures were $1.1 million in Q4 2025, $163000.0 in Q2 2025, and $302000.0 in Q4 2024.